Evidence map›Paper›PMID 41644291›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

CD20-Targeted α-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma.

Shyril O'Steen, Sang Y Lee, Melissa L Comstock, Allie R Kehret, Yukang Lin, Donald K Hamlin, Shannon L Dexter, Daniel S Hippe, Ted A Gooley, D Scott Wilbur and 5 more

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shyril O'SteenTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington; sosteen@fredhutch.org damiangreen@miami.edu.
Sang Y LeeTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Melissa L ComstockTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Allie R KehretTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Yukang LinTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Donald K HamlinDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Shannon L DexterTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Daniel S HippeClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; and.
Ted A GooleyClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; and.
D Scott WilburDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Yawen LiDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Roland B WalterClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; and.
Brian TillClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; and.
Johnnie J OrozcoTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Damian J GreenClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; and sosteen@fredhutch.org damiangreen@miami.edu.

Funding

Radioimmunotherapy Combinations for B-cell MalignancyR01CA076287 · NCI · UNIVERSITY OF WASHINGTON · PI GREEN, DAMIAN J. · 1998 to 2025
$8.1M
NCI NIH HHS R01 CA076287
6 · The paper itself

Abstract

Treatment-refractory and relapsed disease remain leading causes of death for patients with lymphoma. Virtually all lymphomas are exquisitely sensitive to radiation, and α-particle radiation therapies are notably suited to targeting microcluster disease common in the setting of early relapse. Refractory or relapsed lymphoma may also involve the loss of therapeutic targets, but radiation may stimulate antitumor immune effects against disease with incomplete target expression. Such effects make immune checkpoint inhibition a compelling candidate for combination treatment.

Indexed as

Alpha ParticlesAntigens, CD20Immune Checkpoint InhibitorsLymphomaAnimalsCell Line, TumorHumansMiceMice, TransgenicRadioimmunotherapyAntigens, CD20Immune Checkpoint Inhibitorscheckpoint inhibitionimmunocompetent mouse modelslymphomaradioimmunotherapyα-emitters

Identifiers

PMID41644291
PMCPMC13138093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.